Home » FDA Grants Fast-Track Status for HCV-796 for Treatment of Hepatitis C
FDA Grants Fast-Track Status for HCV-796 for Treatment of Hepatitis C
ViroPharma announced that the FDA granted fast-track designation for HCV-796 for treatment of hepatitis C virus (HCV) infection.
HCV-796, an orally dosed non-nucleoside hepatitis C viral polymerase inhibitor that interferes with the replication of HCV, is undergoing Phase II evaluation and is being codeveloped with Wyeth Pharmaceuticals, ViraPharma said.
According to the company, there is no specific antiviral agent directed against HCV that is commercially available, and no vaccine for prevention of HCV infection yet exists.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May